Liquid Suspension Pediatric Formulation

Not all patients are able to swallow TPOXX capsules, the currently-approved oral formulation. To address this unmet need, particularly for pediatric patients weighing less than 13kg who are not covered by the approved label indication for oral TPOXX, SIGA has embarked on a program to develop an oral liquid suspension formulation with funding and support from BARDA.  Formulation prototypes have been generated and will undergo clinical evaluation.